Related Experiment Video
Updated: May 6, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer
Carmen Berasain1, María Ujue Latasa, Raquel Urtasun
1Division of Hepatology and Gene Therapy, CIMA, University of Navarra, Pamplona 31008, Spain. cberasain@unav.es.
Abstract:
Hepatocarcinogenesis is a complex multistep process in which many different molecular pathways have been implicated. Hepatocellular carcinoma (HCC) is refractory to conventional chemotherapeutic agents, and the new targeted therapies are meeting with limited success. Interreceptor crosstalk and the positive feedback between different signaling systems are emerging as mechanisms of targeted therapy resistance. The identification of such interactions is therefore of particular relevance to improve therapeutic efficacy. Among the different signaling pathways activated in hepatocarcinogenesis the epidermal growth factor receptor (EGFR) system plays a prominent role, being recognized as a "signaling hub" where different extracellular growth and survival signals converge. EGFR can be transactivated in response to multiple heterologous ligands through the physical interaction with multiple receptors, the activity of intracellular kinases or the shedding of EGFR-ligands. In this article we review the crosstalk between the EGFR and other signaling pathways that could be relevant to liver cancer development and treatment.
Insights
Understanding crosstalk in liver cancer signaling is key. This review highlights how epidermal growth factor receptor (EGFR) interactions influence hepatocellular carcinoma (HCC) development and treatment resistance.
Area of Science:
- Hepatology and Molecular Oncology
- Cancer Signaling Pathways
Background:
- Hepatocellular carcinoma (HCC) is a complex cancer with limited treatment options.
- Targeted therapies for HCC often face resistance due to intricate signaling networks.
- Interreceptor crosstalk and feedback loops are critical mechanisms driving therapy resistance.
Purpose of the Study:
- To review the crosstalk between the epidermal growth factor receptor (EGFR) and other signaling pathways in liver cancer.
- To identify molecular interactions relevant to hepatocarcinogenesis and therapeutic resistance.
Main Methods:
- Literature review of signaling pathways in hepatocarcinogenesis.
- Analysis of EGFR transactivation mechanisms and interactions.
- Focus on crosstalk relevant to liver cancer development and treatment.
Main Results:
- The epidermal growth factor receptor (EGFR) acts as a central signaling hub in liver cancer.
- EGFR transactivation occurs via heterologous ligands, kinase activity, and ligand shedding.
- Crosstalk involving EGFR significantly impacts liver cancer progression and treatment efficacy.
Conclusions:
- Understanding EGFR crosstalk is crucial for overcoming targeted therapy resistance in HCC.
- Identifying these interactions can lead to improved therapeutic strategies for liver cancer.
- Further research into signaling network interactions is vital for advancing HCC treatment.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
15:05Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Related Concept Videos
Mitogens and the Cell Cycle
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Regulation of Angiogenesis and Blood Supply
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...